{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:47:31Z","timestamp":1792691251153,"version":"4.5.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","award":["899871"],"award-info":[{"award-number":["899871"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","valueinhealthjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jval.2023.12.015","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T16:46:45Z","timestamp":1706546805000},"page":"527-541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["The Cost of Atrial Fibrillation: A Systematic Review"],"prefix":"10.1016","volume":"27","author":[{"given":"Alessandra","family":"Buja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Rebba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Montecchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Renzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Baldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Cocchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Migliore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Zorzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Che\u00efma","family":"Amrouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"De Smedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christodoulos","family":"Kypridemos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Petrovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"O\u2019Flaherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jval.2023.12.015_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccep.2020.10.010","article-title":"Epidemiology of atrial fibrillation: geographic\/ecological risk factors, age, sex, genetics","volume":"13","author":"Zhang","year":"2021","journal-title":"Card Electrophysiol Clin"},{"issue":"17","key":"10.1016\/j.jval.2023.12.015_bib2","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1161\/CIRCULATIONAHA.117.028981","article-title":"Sex differences and similarities in atrial fibrillation epidemiology, risk factors, and mortality in community cohorts: results from the BiomarCaRE consortium (biomarker for cardiovascular risk assessment in Europe)","volume":"136","author":"Magnussen","year":"2017","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jval.2023.12.015_bib5","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/1747493019897870","article-title":"Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge","volume":"16","author":"Lippi","year":"2021","journal-title":"Int J Stroke"},{"issue":"8","key":"10.1016\/j.jval.2023.12.015_bib6","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.amjcard.2013.05.063","article-title":"Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population","volume":"112","author":"Colilla","year":"2013","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.jval.2023.12.015_bib7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/clc.22667","article-title":"Silent atrial fibrillation: epidemiology, diagnosis, and clinical impact","volume":"40","author":"Dilaveris","year":"2017","journal-title":"Clin Cardiol"},{"issue":"6","key":"10.1016\/j.jval.2023.12.015_bib8","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/europace\/euac038","article-title":"How to use digital devices to detect and manage arrhythmias: an EHRA practical guide","volume":"24","author":"Svennberg","year":"2022","journal-title":"Europace"},{"key":"10.1016\/j.jval.2023.12.015_bib9","doi-asserted-by":"crossref","first-page":"i4482","DOI":"10.1136\/bmj.i4482","article-title":"Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis","volume":"354","author":"Odutayo","year":"2016","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.jval.2023.12.015_bib10","doi-asserted-by":"crossref","first-page":"190","DOI":"10.2174\/1573403X10666140902143020","article-title":"How does Chronic atrial fibrillation Influence Mortality in the Modern Treatment Era?","volume":"11","author":"Sankaranarayanan","year":"2015","journal-title":"Curr Cardiol Rev"},{"issue":"4","key":"10.1016\/j.jval.2023.12.015_bib11","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1055\/s-0041-1726332","article-title":"Atrial fibrillation and ischemic stroke: a clinical review","volume":"41","author":"Migdady","year":"2021","journal-title":"Semin Neurol"},{"issue":"8","key":"10.1016\/j.jval.2023.12.015_bib12","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1177\/2047487314538855","article-title":"Health-related quality of life in atrial fibrillation patients over 65 years: a review","volume":"22","author":"Zhang","year":"2015","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"10.1016\/j.jval.2023.12.015_bib13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/WCO.0000000000000780","article-title":"Atrial fibrillation and stroke: how much atrial fibrillation is enough to cause a stroke?","volume":"33","author":"Healey","year":"2020","journal-title":"Curr Opin Neurol"},{"issue":"8","key":"10.1016\/j.jval.2023.12.015_bib14","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/ehjqcco\/qcac005","article-title":"Targeted vs. full population screening costs for incident atrial fibrillation and AF-related stroke for a healthy population aged 65 years in the United Kingdom","volume":"8","author":"Burdett","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"3","key":"10.1016\/j.jval.2023.12.015_bib15","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1055\/s-0040-1716408","article-title":"The 4S-AF scheme (stroke risk; symptoms; severity of burden; substrate): a novel approach to in-depth characterization (Rather than classification) of atrial fibrillation","volume":"121","author":"Potpara","year":"2021","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.jval.2023.12.015_bib16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1055\/s-0041-1739411","article-title":"2021 Focused update consensus guidelines of the Asia Pacific heart rhythm society on stroke prevention in atrial fibrillation: executive summary","volume":"122","author":"Chao","year":"2022","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.jval.2023.12.015_bib17","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3350\/cmh.2014.20.4.327","article-title":"Cost-of-illness studies: concepts, scopes, and methods","volume":"20","author":"Jo","year":"2014","journal-title":"Clin Mol Hepatol"},{"issue":"16","key":"10.1016\/j.jval.2023.12.015_bib18","doi-asserted-by":"crossref","first-page":"e750","DOI":"10.1161\/CIR.0000000000000748","article-title":"Lifestyle and risk factor modification for reduction of atrial fibrillation: a scientific statement from the American Heart Association","volume":"141","author":"Chung","year":"2020","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.jval.2023.12.015_bib19","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2217\/cer-2019-0089","article-title":"Systematic review of societal costs associated with stroke, bleeding and monitoring in atrial fibrillation","volume":"8","author":"Martin","year":"2019","journal-title":"J\u00a0Comp Eff Res"},{"issue":"10","key":"10.1016\/j.jval.2023.12.015_bib20","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/europace\/eur194","article-title":"The cost of illness of atrial fibrillation: a systematic review of the recent literature","volume":"13","author":"Wolowacz","year":"2011","journal-title":"Europace"},{"issue":"2","key":"10.1016\/j.jval.2023.12.015_bib21","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jval.2011.09.009","article-title":"A\u00a0review of the cost of atrial fibrillation","volume":"15","author":"Wodchis","year":"2012","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.jval.2023.12.015_bib22","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1586\/14737167.2014.940904","article-title":"Cost-of-illness studies of atrial fibrillation: methodological considerations","volume":"14","author":"Becker","year":"2014","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"8","key":"10.1016\/j.jval.2023.12.015_bib23","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s10198-018-0961-7","article-title":"Annual costs attributed to atrial fibrillation management: cross-sectional study of primary healthcare electronic records","volume":"19","author":"Casajuana","year":"2018","journal-title":"Eur J Health Econ"},{"issue":"9","key":"10.1016\/j.jval.2023.12.015_bib24","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/europace\/eur116","article-title":"The costs of atrial fibrillation in patients with cardiovascular comorbidities--a longitudinal analysis of German health insurance data","volume":"13","author":"Reinhold","year":"2011","journal-title":"Europace"},{"key":"10.1016\/j.jval.2023.12.015_bib25","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.jval.2023.12.015_bib26","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/j.1524-4733.2008.00327.x","article-title":"Methodological considerations in cost of prostate cancer studies: a systematic review","volume":"11","author":"Molinier","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2023.12.015_bib27","series-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2015"},{"issue":"3","key":"10.1016\/j.jval.2023.12.015_bib28","first-page":"241","article-title":"The economic burden of hypertension, heart failure, myocardial infarction, and atrial fibrillation in Mexico","volume":"88","author":"Stevens","year":"2018","journal-title":"Arch Cardiol Mex"},{"issue":"1","key":"10.1016\/j.jval.2023.12.015_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.repc.2014.08.005","article-title":"Burden of disease and cost of illness of atrial fibrillation in Portugal","volume":"34","author":"Gouveia","year":"2015","journal-title":"Rev Port Cardiol"},{"issue":"5","key":"10.1016\/j.jval.2023.12.015_bib30","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10198-010-0261-3","article-title":"Atrial fibrillation: the cost of illness in Sweden","volume":"12","author":"Ericson","year":"2011","journal-title":"Eur J Health Econ"},{"issue":"9","key":"10.1016\/j.jval.2023.12.015_bib31","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s12471-011-0175-4","article-title":"The burden of atrial fibrillation in the Netherlands","volume":"19","author":"Heemstra","year":"2011","journal-title":"Neth Heart J"},{"issue":"2","key":"10.1016\/j.jval.2023.12.015_bib32","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/ehjqcco\/qcaa093","article-title":"Atrial fibrillation in the UK: predicting costs of an emerging epidemic recognizing and forecasting the cost drivers of atrial fibrillation-related costs","volume":"8","author":"Burdett","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"3","key":"10.1016\/j.jval.2023.12.015_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-028575","article-title":"A\u00a0two-part model to estimate inpatient, outpatient, prescribing and care home costs associated with atrial fibrillation in Scotland","volume":"10","author":"Ciminata","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.jval.2023.12.015_bib34","series-title":"Hospital and clinical care costs associated with atrial fibrillation for Medicare beneficiaries in the cardiovascular Health Study and the Framingham Heart Study","volume":"6","author":"Delaney","year":"2018"},{"issue":"1","key":"10.1016\/j.jval.2023.12.015_bib35","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1186\/s12913-017-2652-y","article-title":"Cost of illness of atrial fibrillation: a nationwide study of societal impact","volume":"17","author":"Johnsen","year":"2017","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"10.1016\/j.jval.2023.12.015_bib36","first-page":"175","article-title":"The cost of atrial fibrillation in Italy: a five-year analysis of healthcare expenditure in the general population. From the Italian Survey of atrial fibrillation Management (ISAF) study","volume":"21","author":"Zoni Berisso","year":"2017","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"5","key":"10.1016\/j.jval.2023.12.015_bib37","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.amjcard.2015.05.045","article-title":"Economic burden of undiagnosed nonvalvular atrial fibrillation in the United States","volume":"116","author":"Turakhia","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jval.2023.12.015_bib38","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212254","article-title":"The non-anticoagulation costs of atrial fibrillation management: findings from an observational study in NHS Primary Care","volume":"3","author":"Kassianos","year":"2014","journal-title":"Drugs Context"},{"issue":"10","key":"10.1016\/j.jval.2023.12.015_bib39","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s12325-011-0065-6","article-title":"Incremental cost burden to US healthcare payers of atrial fibrillation\/atrial flutter patients with additional risk factors","volume":"28","author":"Amin","year":"2011","journal-title":"Adv Ther"},{"issue":"3","key":"10.1016\/j.jval.2023.12.015_bib40","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1161\/CIRCOUTCOMES.110.958165","article-title":"Estimation of total incremental health care costs in patients with atrial fibrillation in the United States","volume":"4","author":"Kim","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"1","key":"10.1016\/j.jval.2023.12.015_bib41","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/europace\/euq325","article-title":"Predictors of costs related to cardiovascular disease among patients with atrial fibrillation in five European countries","volume":"13","author":"Holstenson","year":"2011","journal-title":"Europace"},{"issue":"5","key":"10.1016\/j.jval.2023.12.015_bib42","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2165\/11319880-000000000-00000","article-title":"Cost of illness and drivers of cost in atrial fibrillation in Sweden and Germany","volume":"8","author":"J\u00f6nsson","year":"2010","journal-title":"Appl Health Econ Health Policy"},{"issue":"4","key":"10.1016\/j.jval.2023.12.015_bib43","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/JOM.0b013e3181d967bc","article-title":"The burden of atrial fibrillation and other cardiac arrhythmias in an employed population: associated costs, absences, and objective productivity loss","volume":"52","author":"Rohrbacker","year":"2010","journal-title":"J\u00a0Occup Environ Med"},{"issue":"5","key":"10.1016\/j.jval.2023.12.015_bib44","first-page":"639","article-title":"A\u00a0real-world observational study of hospitalization and health care costs among nonvalvular atrial fibrillation patients prescribed oral anticoagulants in the U.S. Medicare population","volume":"26","author":"Amin","year":"2020","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"12","key":"10.1016\/j.jval.2023.12.015_bib45","first-page":"1338","article-title":"Healthcare resource utilization and expenditures among newly-diagnosed elderly non-valvular atrial fibrillation patients initiating oral anticoagulants","volume":"22","author":"Chowdhury","year":"2019","journal-title":"J\u00a0Med Econ"},{"issue":"2","key":"10.1016\/j.jval.2023.12.015_bib46","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/03007995.2017.1409425","article-title":"Comparison of all-cause costs and healthcare resource use among patients with newly-diagnosed non-valvular atrial fibrillation newly treated with oral anticoagulants","volume":"34","author":"Gilligan","year":"2018","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1016\/j.jval.2023.12.015_bib47","first-page":"73","article-title":"Health care resource utilization and costs among newly diagnosed and oral anticoagulant-naive nonvalvular atrial fibrillation patients treated with dabigatran or warfarin in the United States","volume":"24","author":"Jain","year":"2018","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"4","key":"10.1016\/j.jval.2023.12.015_bib48","article-title":"Identifying predictors of cumulative healthcare costs in incident atrial fibrillation: a population-based study","volume":"4","author":"Bennell","year":"2015","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.jval.2023.12.015_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1540-8167.2011.02130.x","article-title":"Healthcare utilization and expenditures in patients with atrial fibrillation treated with catheter ablation","volume":"23","author":"Ladapo","year":"2012","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"issue":"1","key":"10.1016\/j.jval.2023.12.015_bib50","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12889-020-10084-x","article-title":"Trends of multimorbidity in 15 European countries: a population-based study in community-dwelling adults aged 50 and over","volume":"21","author":"Souza","year":"2021","journal-title":"BMC Public Health"},{"issue":"8","key":"10.1016\/j.jval.2023.12.015_bib51","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2666-7568(21)00146-X","article-title":"Inequalities in incident and prevalent multimorbidity in England, 2004-19: a population-based, descriptive study","volume":"2","author":"Head","year":"2021","journal-title":"Lancet Healthy Longev"},{"key":"10.1016\/j.jval.2023.12.015_bib52","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2147\/RMHP.S97248","article-title":"Multimorbidity in chronic disease: impact on health care resources and costs","volume":"9","author":"McPhail","year":"2016","journal-title":"Risk Manag Healthc Policy"},{"issue":"1","key":"10.1016\/j.jval.2023.12.015_bib53","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s12916-022-02427-9","article-title":"Costs of multimorbidity: a systematic review and meta-analyses","volume":"20","author":"Tran","year":"2022","journal-title":"BMC Med"},{"issue":"12","key":"10.1016\/j.jval.2023.12.015_bib54","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1055\/s-0042-1756355","article-title":"Clinical complexity domains, anticoagulation, and outcomes in patients with atrial fibrillation: a report from the Gloria-AF registry Phase II and III","volume":"122","author":"Romiti","year":"2022","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.jval.2023.12.015_bib55","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1186\/s12916-022-02526-7","article-title":"Clinical complexity and impact of the\u00a0+ (Atrial fibrillation Better Care) pathway in patients with atrial fibrillation: a report from the ESC-EHRA EURObservational Research Programme in AF General Long-Term Registry","volume":"20","author":"Romiti","year":"2022","journal-title":"BMC Med"},{"issue":"10","key":"10.1016\/j.jval.2023.12.015_bib56","first-page":"E1","volume":"60","year":"2012","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"suppl 1","key":"10.1016\/j.jval.2023.12.015_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5414\/CPP52S001","article-title":"Recommendations for treating adult and geriatric patients on multimedication","volume":"52","author":"Bergert","year":"2014","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.jval.2023.12.015_bib60","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1055\/a-1515-9630","article-title":"Adherence to the \u2018atrial fibrillation better care\u2019 pathway in patients with atrial fibrillation: impact on clinical outcomes-a systematic review and meta-analysis of 285,000 patients","volume":"122","author":"Romiti","year":"2022","journal-title":"Thromb Haemost"},{"issue":"12","key":"10.1016\/j.jval.2023.12.015_bib61","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.40071","article-title":"mAF-App II Trial Investigators. The effects of implementing a mobile health-technology supported pathway on atrial fibrillation-related adverse events among patients with multimorbidity: the mAFA-II randomized clinical trial","volume":"4","author":"Yao","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"31","key":"10.1016\/j.jval.2023.12.015_bib63","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1093\/eurheartj\/ehac265","article-title":"A\u00a0multinational European network to implement integrated care in elderly multimorbid atrial fibrillation patients: the AFFIRMO Consortium","volume":"43","author":"Johnsen","year":"2022","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.jval.2023.12.015_bib64","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10198-018-0984-0","article-title":"Economic burden of stroke: a systematic review on post-stroke care","volume":"20","author":"Rajsic","year":"2019","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.jval.2023.12.015_bib65","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijcard.2018.11.087","article-title":"Cost-effectiveness of Rivaroxaban versus warfarin for treatment of nonvalvular atrial fibrillation in patients with worsening renal function","volume":"282","author":"Salcedo","year":"2019","journal-title":"Int J Cardiol"},{"issue":"4","key":"10.1016\/j.jval.2023.12.015_bib66","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/jcpt.13575","article-title":"Cost-effectiveness of anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation in mainland","volume":"47","author":"Zhou","year":"2022","journal-title":"Chin. J Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.jval.2023.12.015_bib67","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jsps.2022.11.010","article-title":"Cost effectiveness of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients in Saudi Arabia: A Single-Center retrospective cohort study","volume":"31","author":"AlRuthia","year":"2023","journal-title":"Saudi Pharm J"},{"issue":"2","key":"10.1016\/j.jval.2023.12.015_bib68","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2021-001737","article-title":"Anticoagulation trends in adults aged 65 years and over with atrial fibrillation: a cohort study","volume":"8","author":"Lund","year":"2021","journal-title":"Open Heart"},{"issue":"6","key":"10.1016\/j.jval.2023.12.015_bib69","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1161\/CIRCRESAHA.117.311849","article-title":"Reducing the global burden of cardiovascular disease, part 2: prevention and treatment of cardiovascular disease","volume":"121","author":"Leong","year":"2017","journal-title":"Circ Res"},{"issue":"3","key":"10.1016\/j.jval.2023.12.015_bib70","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1017\/S0266462310000322","article-title":"Modeling in pharmacoeconomic studies: funding sources and outcomes","volume":"26","author":"Garattini","year":"2010","journal-title":"Int J Technol Assess Health Care"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301524000354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301524000354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T16:10:01Z","timestamp":1730391001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301524000354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1098301524000354"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2023.12.015","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Cost of Atrial Fibrillation: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2023.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}